NCT06423261View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Immunogenicity Study of GB002 Recombinant Peptide Inhalation Solution in Healthy Subjects

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

August 24, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

July 29, 2026

Conditions

Healthy

Interventions

DRUG

GB002 Recombinant Peptide Inhalation Solution

Inhalation administration

DRUG

Placebo

Inhalation administration

Trial Locations (1)

410015

The Third Hospital of Changsha, Changsha

All Listed Sponsors

lead

Zhejiang Echon Biopharm Limited

INDUSTRY

NCT06423261 - Safety, Tolerability, Pharmacokinetics and Immunogenicity Study of GB002 Recombinant Peptide Inhalation Solution in Healthy Subjects | Biotech Hunter | Biotech Hunter